More recently, clinical studies employing humanized variants of mAb120.545 that target STEAP1 were conducted, including 1) a phase I trial using an antibody-drug conjugate (termed DSTP3086S or Vandortuzumab Vedotin) to target prostate cancer (6, –, 8) and 2) a combined phase I/phase II trial for the PET imaging of metastatic castration-resistant prostate cancer using Zr89-labelled antibody (termed [89Zr]Zr-DFO-MSTP2109A) (9, –, 11). The gene discussed is STEAP1; the disease is prostate cancer.